Results of transurethral resection and intravesical doxorubicin prophylaxis in patients with T1 G3 bladder cancer

Prognostic significance of platelet‐derived endothelial cell growth factor/thymidine phosphorylase expression in stage pT1 G3 bladder cancer

“…However, the progression rate in this study was 26.7%. Bono et al reported disease progression in 23.4% of patients with primary pT1 G3 tumors treated with doxorubicin 19 . The lower progression rate in this study might be due to adjuvant intravesical chemotherapy.…”

Transurethral Resection and Sequential Chemo–Immunoprophylaxis in Primary T1G3 Bladder Cancer

“…In an analysis of 1,706 T1 patients treated with various modalities, it appeard that the average progression rates in patients with T1G3 tumors treated by TURBT alone, TURBT plus intravesical chemotherapy and TURBT plus intravesical BCG were 31, 19 and 17–25%, respectively [2, 10, 11](table 3). In one of the largest series on primary T1G3 tumors published, we found a progression rate of 23% in 128 primary T1G3 patients treated by TUR followed by intravesical doxorubicin with a disease–specific mortality rate of only 8% after 6 years of average follow–up [1]. …”

“…One of the current challenges in urologic practice is to identify, through clinically applicable prognostic criteria, those patients most likely to progress. In our previous study on primary T1G3 bladder cancer [1], we identified recurrence of T1G3 tumor as the most important predictor of subsequent progression and death. This finding is in agreement with another study, which showed that the recurrence of T1 tumor 6 months after treatment with BCG was the most significant variable predictive of late muscle invasion [12].…”

“…In a previous study we obtained very good long–term results in a group of T1G3 patients treated with TURBT followed by intravesical prophylaxis with doxorubicin [1]. Various studies have shown that BCG prophylaxis is probably superior to cytotoxic agents in the control of high–risk transitional cell carcinoma of the bladder [2, 3].…”

T1 GIII Bladder Cancer

“…Bono et al found the reappearance of T1 GIII tumor on first recurrence was the only factor correlated with progression [4]. Although chromosomal markers and the deletion of surface ABH antigens have been found in a significant number of patients with tumor progression, their relevance remains to be seen.…”